Aaron BenComo, Chief Medical Officer, Phronetik

In an interview with Invest:, Aaron BenComo, chief medical officer at Phronetik, emphasized the company’s mission to make precision medicine accessible to marginalized and underrepresented communities through data science and genomics. He highlighted North Texas as a growing biotech hub, citing its strong research institutions, entrepreneurial spirit, investment culture, and cost-effectiveness as key drivers of growth.

What is Phronetik’s mission, and how is it driving innovation in precision medicine and biotechnology?

Phronetik is a clinical research organization focused on data science and precision medicine. Precision medicine is about treating individuals based on their unique genetic makeup rather than applying a one-size-fits-all approach. At Phronetik, we take this concept further by prioritizing inclusivity and ensuring our research represents the full diversity of the population.

Many medical advancements fail to reach underrepresented communities due to systemic barriers and a lack of outreach. We aim to bridge these gaps by combining cutting-edge genomic analysis with grassroots community engagement — ensuring innovation benefits everyone, not just a select few.

Our mission is to make precision medicine accessible to all by addressing long-standing gaps in healthcare research and delivery. These disparities extend beyond gender and genetics to include rural populations, communities of color, women, and low-resource areas — groups that have historically been underrepresented in clinical research and underserved in healthcare.

To tackle these challenges, we engage with communities, collect meaningful data, and leverage our proprietary technologies — iHarmony and iConcordia. These platforms allow us to analyze genomic data and provide personalized healthcare solutions tailored to the diverse needs of different populations.

What initially drew me to Phronetik was the company’s commitment to documenting and highlighting the important work being done in the region, ensuring that progress is both recognized and measurable. However, what truly resonated with me was learning about healthcare disparities — such as the fact that the FDA didn’t mandate the inclusion of women in clinical trials until the mid-1990s. That realization made me question how many treatments were developed without considering key demographic differences. It inspired me to be part of a solution that prioritizes inclusivity in precision medicine.

Phronetik is focused on expanding its reach and further integrating precision medicine into underserved communities. I’m especially excited about the potential of our proprietary technologies to drive real change in how healthcare is delivered and personalized.

What makes North Texas unique compared to other biomed hubs?

My experience in clinical medicine before moving to Dallas gave me a unique perspective, especially as a native Houstonian. Typically, people from Houston don’t see themselves moving to Dallas unless there’s an exceptional opportunity — and that’s exactly what I found here. I saw incredible potential and key advantages that make North Texas a rising biotech hub.

One of the critical components to success in this industry is having high-caliber research and academic institutions that produce intellectual property (IP). North Texas has that, with four R1 research institutions and more than a dozen nationally ranked academic centers of excellence.

Another essential factor is investment. Dallas-Fort Worth has a strong culture of investment, historically rooted in industries like real estate, oil, and finance. That culture now extends into biotech, supported by corporate partnerships with institutions like SMU and companies such as NVIDIA. This influx of investment, both public and private, has been crucial to the region’s growth. Plus, support from high-net-worth individuals like Lyda Hill, whose contributions at Pegasus Park and BioLabs have been instrumental.

But it’s not just about having research and investment; success comes from real-world wins. Over the past few years, North Texas has seen multiple major exits, including billion-dollar deals and numerous acquisitions and mergers. The talent is here too — North Texas consistently ranks as one of the top regions for STEM graduates and entrepreneurship.

Cost-effectiveness is another significant advantage. In traditional biotech hubs like the coasts or the Great Lakes region, development costs have skyrocketed. North Texas offers a more affordable alternative, attracting companies from major hubs like Boston, San Francisco, and Arizona. In North Texas you get a “San Francisco or Boston-level” opportunity at a fraction of the cost. The potential for growth and return on investment here is truly exceptional.

Crucially, North Texas has a unique ability to retain talent. Many cities struggle to keep their workforce, but here, people are staying. This retention is largely due to the region’s robust academic ecosystem and the quality of life it offers.

From a logistics standpoint, North Texas is also strategically positioned. With its central location, it’s less than a four-hour flight to either coast, making it easier for executives and stakeholders to travel in and out. Additionally, Dallas-Fort Worth International Airport is one of only two airports in the U.S. with ISCC certification for end-to-end cold chain storage — critical for temperature-sensitive pharmaceuticals and vaccines.

What services at Phronetik are seeing the most demand, and where do you see growth opportunities? 

Right now, one of our primary focuses is next-generation diagnostic testing, which goes hand in hand with precision medicine and cell and gene therapy. This is a rapidly growing sector, and North Texas is well-positioned to support it, thanks to its robust ecosystem.

The region offers everything needed to support the full lifecycle of precision medicine — from the initial research and intellectual property development to clinical trials and commercialization. We see an increasing number of oncology companies launching here, as well as a strong presence of clinical research organizations (CROs) that support these efforts.

In terms of demand, cell and gene therapy, precision medicine, and rare disease research are all areas of significant growth. UT Southwestern plays a major role in driving these advancements, and companies like Lantern Pharma in Dallas are leveraging AI for drug discovery, pushing the boundaries of personalized medicine.

Looking ahead, I believe the future of healthcare is personalized, and North Texas is uniquely positioned to lead the way from research to implementation.

What are Phronetik’s priorities for the coming years, and what’s your outlook on the region’s growth? 

Our short-to-medium-term goals are focused on expanding our proprietary technologies, iHarmony and iConcordia, to provide actionable genomic insights. We’re also working to establish more partnerships across the U.S. and have ambitions to expand internationally.

We believe that, once fully optimized, Phronetik will be able to provide immediate, remote genomic analysis to healthcare providers worldwide — including private institutions and government agencies such as the NIH and WHO.

As for the region, I’m incredibly optimistic. North Texas has all the right ingredients for success — talent, investment, infrastructure, and a strong economy. Unlike other markets, it still has room for growth, and the region’s commitment to innovation makes it an attractive destination for companies looking to scale. There’s a real sense of teamwork and shared vision — whether you’re an established company or a startup, people are willing to support and work together to help the region grow.

North Texas is no longer just an emerging biotech hub — it’s quickly becoming a key player in the industry, and I believe we’re only scratching the surface of what’s possible here.